Our specialist medical device team work with diverse global companies within the industry to sustain growth, exploit current and future innovations, and secure their business's success. Our clients are multinational corporations and start-ups within the medical devices industry from companies within medical devices or in vitro diagnostic medical devices.
With sector-specific expertise grounded in scientific intelligence and technological know-how, clients value our knowledge of the regulatory frameworks shaping clients' strategic options, the technology being deployed, and our ability to execute complex legal solutions across multi-jurisdictions.
We ensure that our clients operate within the boundaries of medical regulations, data privacy, competition/anti-trust, procurement, pricing and reimbursement, advertising and promotion, and anti-bribery compliance/fraud and abuse laws.
We are pivotal in leveraging growth through strategic alliances, fundraisings, IP and compliant data privacy and security activities, and are relied on to resolve both offensive and defensive cross-jurisdiction patent litigation.
With in-depth sector expertise, we also actively engage with the wider medical devices industry through our connections with esteemed industry bodies and as leading voices in industry publications and wider expert webinar/seminar series.
Die börsennotierte Eckert & Ziegler Strahlen- und Medizintechnik AG, einer der weltweit größten Anbieter von isotopentechnischen Komponenten für Strahlentherapie und Nuklearmedizin mit Sitz in Berlin, hat die ebenfalls börsennotierte belgische Eckert & Ziegler BEBIG SA übernommen. Die internationale Wirtschaftskanzlei Taylor Wessing hat die Eckert & Ziegler Strahlen- und Medizintechnik AG hinsichtlich aller Aspekte der grenzüberschreitenden Verschmelzung rechtlich beraten. Die Transaktion dürfte die erste erfolgreiche Umsetzung einer grenzüberschreitenden Verschmelzung zweier börsennotierter Gesellschaften nach Deutschland auf der Grundlage der europäisch harmonisierten Vorgaben der EU-Gesellschaftsrichtlinie (EU) 2017/1132 sein.
Press release
Aktuelle News & Insights
Preliminary injunctions in the UPC – lessons learnt
Two years in, the UPC has become a key forum for patent enforcement, offering swift preliminary injunctions across many EU states. Courts assess both infringement and patent validity rigorously, requiring applicants to act quickly and prepare thoroughly.
von Mag. Thomas Adocker und Christian Dekoninck
2 von 5 Insights
UPC litigation in life sciences: seven early takeaways for the pharma, biotech and medical devices sectors
The Unified Patent Court (UPC) has become a crucial forum for life sciences patent litigation. Early rulings show strict claim interpretation, careful review of European Patent Office oppositions, and limits on the Bolar exemption. The UPC has clarified infringement tests for second medical use claims and considers patient interests in injunctions. These developments emphasise precise patent strategy, regulatory alignment, and proactive risk management for pharma, biotech, and medical device sectors.
von Yolandi Coetzee und Pauline Springorum
1 von 5 Insights
The UPC going beyond its borders: how your company can profit from the latest case law
The UPC now allows life sciences companies to enforce European patents more efficiently across multiple countries through its long-arm jurisdiction. This lets patent holders sue distributors based in UPC member states in a single action, even if products are sold or made in non-UPC countries. Following key rulings the UPC can issue cross-border injunctions covering several national patent parts, while respecting jurisdiction limits on patent validity challenges.
von Dr. Anja Lunze, LL.M. und Verena Bertram
5 von 5 Insights
UK to maintain current exhaustion of rights regime
von Louise Popple
Updated post-market surveillance (PMS) rules for medical devices in the UK: differences from the EU regulations
von Alison Dennis und Alice Matthews